Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.15 HKD | +7.79% | +22.78% | -17.98% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 57% by 2026.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company shows low valuation levels, with an enterprise value at 1.03 times its sales.
- The company's share price in relation to its net book value makes it look relatively cheap.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-17.98% | 562M | - | ||
+4.36% | 32.47B | C | ||
+14.14% | 7.45B | C- | ||
+22.93% | 3.89B | B- | ||
-16.29% | 3.17B | C- | ||
-25.96% | 1.28B | B | ||
-36.14% | 1.09B | - | ||
-35.42% | 902M | - | ||
-0.13% | 893M | C | ||
-24.12% | 857M | - | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 2158 Stock
- Ratings Yidu Tech Inc.